27883-60-9

Basic information

• Product Name: 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER;Methyl 4-hydroxy-5-Methoxy-2-nitrobenzoate;4-hydroxy-5-methoxy-2-nitrobenzoic acid
• CAS NO: 27883-60-9
• Molecular Formula: C₉H₉NO₆
• Molecular Weight: 227.17086
• Mol File: 27883-60-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 389.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.405±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 6.63±0.24(Predicted)
• CAS DataBase Reference: 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(27883-60-9)
• EPA Substance Registry System: 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(27883-60-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 27883-60-9(Hazardous Substances Data)

Usage

General Description

4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER is a chemical compound that is derived from benzoic acid and contains a nitro group, a hydroxyl group, and a methoxy group. It is commonly used in the production of pharmaceuticals and dyes, as well as in organic synthesis. 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER has shown potential as an anti-inflammatory and analgesic agent, and has been studied for its potential therapeutic applications. 4-HYDROXY-5-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER is a versatile chemical with various industrial applications and potential medicinal uses.

Upstream product

• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 10097-32-2 bromine 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 1486-53-9 4-(benzyloxy)-3-methoxybenzoic acid 
• 121-33-5 vanillin 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 67-56-1 methanol 
• 140647-01-4 4-hydroxy-5-methoxy-2-nitrobenzoic acid 
• 91203-74-6 4-benzyloxy-3-methoxybenzoic acid benzyl ester 
• 60547-92-4 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid 

Downstream Products

• 364793-68-0 5-methoxy-2-nitro-4-trifluoromethanesulfonyloxy-benzoic acid methyl ester 
• 757189-84-7 methyl 4-(N-t-butoxycarbonyl)aminoethoxy-5-methoxy-2-nitrobenzoate 
• 757189-85-8 methyl 4-(N-t-butoxycarbonyl)aminopropoxy-5-methoxy-2-nitrobenzoate 
• 175733-04-7 (2S)-N-[4-(2-aminoethoxy)-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 745014-30-6 (2S)-N-[4-(3-aminopropoxy)-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 745014-24-8 (2S)-N-[4-(N-t-butoxycarbonyl)aminoethoxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 745014-29-3 (2S)-N-[4-(N-t-butoxycarbonyl)aminopropoxy-5-methoxy-2-nitrobenzoyl]pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 757189-86-9 4-(N-t-butoxycarbonyl)aminoethoxy-5-methoxy-2-nitrobenzoic acid 
• 757189-87-0 4-(3-((tert-butoxycarbonyl)amino)propoxy)-5-methoxy-2-nitrobenzoic acid 
• 757190-01-5 (2S)-N-{4-[(2S)-N-(4,5-dimethoxy-2-aminobenzoyl)-pyrrolidine-2-carboxaldehyde diethyl thioacetal-4-(carboxamidomethylidene)-N-ethyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 757189-97-2 (2S)-N-{4-[(2S)-N-(4,5-dimethoxy-2-nitrobenzoyl)-pyrrolidine-2-carboxaldehyde diethyl thioacetal-4-(carboxamidomethylidene)-N-ethyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 757190-02-6 (2S)-N-{4-[(2S)-N-(4,5-dimethoxy-2-aminobenzoyl)-pyrrolidine-2-carboxaldehyde diethyl thioacetal-4-(carboxamidomethylidene)-N-propyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 757189-98-3 (2S)-N-{4-[(2S)-N-(4,5-dimethoxy-2-nitrobenzoyl)-pyrrolidine-2-carboxaldehyde diethyl thioacetal-4-(carboxamidomethylidene)-N-propyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 
• 757189-99-4 (2S)-N-{4-[(2S)-N-(4-benzyloxy-5-methoxy-2-aminobenzoyl)-pyrrolidine-2-carboxaldehyde diethyl thioacetal-4-(carboxamidomethylidene)-N-ethyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 

Relevant articles and documents

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

Using knowledge- and structure-based approaches, we designed and synthesized reversible chemical probes that simultaneously inhibit the activity of two epigenetic targets, histone 3 lysine 9 methyltransferase (G9a) and DNA methyltransferases (DNMT), at nanomolar ranges. Enzymatic competition assays confirmed our design strategy: substrate competitive inhibitors. Next, an initial exploration around our hit 11 was pursued to identify an adequate tool compound for in vivo testing. In vitro treatment of different hematological neoplasia cell lines led to the identification of molecules with clear antiproliferative efficacies (GI50 values in the nanomolar range). On the basis of epigenetic functional cellular responses (levels of lysine 9 methylation and 5-methylcytosine), an acceptable therapeutic window (around 1 log unit) and a suitable pharmacokinetic profile, 12 was selected for in vivo proof-of-concept (Nat. Commun. 2017, 8, 15424). Herein, 12 achieved a significant in vivo efficacy: 70% overall tumor growth inhibition of a human acute myeloid leukemia (AML) xenograft in a mouse model.